Study Protocol:  
Open -label study of Maraviroc in Hospi[INVESTIGATOR_480675] -CoV-2 
[STUDY_ID_REMOVED]  
Version Date: 11/6/ 2020  
Protocol : Open -Label Study  of Maraviroc in Hospi[INVESTIGATOR_480676] s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 1 of 30 
   PHILIP A . CHAN MD, MS  
Clinical Research Protocol  
OPEN -LABEL STUDY OF MARAVIROC IN HOSPI[INVESTIGATOR_480677] -COV -2 
Version Date:  11/6/ /[ADDRESS_617700]:  Maraviroc  
IND Number:  PI[INVESTIGATOR_47967]  150411 , IND exempt  
Deve lopment Phase : Phase 1  
Sponsor:  Department of Medicine   
Principal Investigator:  [CONTACT_5627]:  Philip A. Chan MD,  MS   
Telephone:  ([PHONE_10053]   
Fax: (401) 793 -4709    
E-mail:  [EMAIL_9254]   
Medical Monitor:  Name:  [CONTACT_480718]:  ([PHONE_10054]  
E-mail:  tflanig [EMAIL_9255]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol : Open -Label Study  of Maraviroc in Hospi[INVESTIGATOR_480676] s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/[ADDRESS_617701].  
  STUDY DESIGN  Single -arm, Open -Label, Proof -of-Concept  
  PRIMA RY 
OBJECTIVE  To establish wh ether Maraviroc, used at its approv ed dosage for HIV, 
is safe and effective in hospit alized  patients with SAR S-CoV-2. 
  SECONDARY 
OBJECTIVES  Investigate the relationship between reduction of inflammatory and 
other bio markers (such as IL -6, CCL5, etc.) later in the course of 
infection and avoidance of respi[INVESTIGATOR_480678].  
  NUMB ER OF 
SUBJECTS  [ADDRESS_617702] 
SELECTION  
CRITERIA  Inclusion Criteria : 
• Male or female ≥ 18 years of age at time of screening    
• Documentation of a SA RS-CoV -2 diagnosis as evidenced by 
[CONTACT_95570] S ARS -CoV-2 PC R within twelve  days at time of 
screening  
• Chest radiography co nsistent w ith multi -focal pneumonia or 
air-space disease  
• Written informed consent obtained from  subject  and ab ility for 
subject to comply w ith the requirements of the study.  
• Subject able to safely swal low pi[INVESTIGATOR_480679] h a nasogastric or  orogastric tube.  
Exclusion Criteria : 
• Subjects who are pregna nt, breast feeding, or unwilling to pra ctice 
birth control du ring participation in the study.  
• Subjects with the pr esence of a c ondition or abn ormality that in 
the opi[INVESTIGATOR_3078] n of the Investigator s woul d compr omise the safety of 
Protocol : Open -Label Study  of Maraviroc in Hospi[INVESTIGATOR_480676] s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/[ADDRESS_617703] 6 months, 
neurological, psychiatr ic, endocrin e, or neoplastic  diseases that 
are judged to interf ere with participa tion in  the study.  
• Subjects with k nown diagnosis of human immu nodeficien cy 
virus infection (HIV)  
• Subjects enrolled in anot her interventional trial (includi ng one for 
COVID -19) that exclud es participation  in other trials or  includ es 
a pote nt CYP3A inhibitor  or inducer (e.g. lopi[INVESTIGATOR_054] -riton avir) .  
• Subjects with ESRD or severe renal failure who are taking potent 
(moderate or str ong) CYP3A inhibito rs or inducers  
 
  TEST PRODUCT, 
DOSE,  AND RO UTE 
OF 
ADMINIS TRATION  Maraviroc will be ad ministere d orally twice dai ly for seven days.     
    DURATION OF 
SUBJECT 
PARTICIPATI ON 
AND DUR ATION OF 
STUDY  Subjects will be on study for up to  35 days 
Treatment:  7 days  
Follow -up:  [ADDRESS_617704] follow -up and 1 mon th for 
data run-off and analysis . 
E  CONCOMMI TAN T 
MEDICATIONS  Prohibi ted: 
Lopi[INVESTIGATOR_054] -Tenofovir  
Hydroxychloroquine  
Ivermectin  
  EFFICACY 
EVALUATIONS   
PRIMARY ENDPOINT  • In this pr oof-of-conce pt trial, the stud y team is  chiefly concerned 
with safety and tolerabilit y of Marav iroc in subjects diagnosed 
with SARS -CoV -2.  The primary endpoint  is rate of subjects  who 
complete the 7 -day co urse of Mara viroc without discontinuati on 
for serious adverse event  or death.  Additional  endpoints include 
the percent of study population reaching clinical im provement , 
defined as t ime fro m enrollment  to an improvement of two  points 
on a seven-category ordinal scale  (defined below) , at Day 7. 
SECONDARY 
END POINTS  • Time to improvement to Score of 2 or less (Days)   based on 
Ordinal scale : 1, not hospi[INVESTIGATOR_480680]; 2, not hos pi[INVESTIGATOR_057],  but un able to resume normal 
Protocol : Open -Label Study  of Maraviroc in Hospi[INVESTIGATOR_480676] s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 4 of 30 
 activities  OR hospi[INVESTIGATOR_480681] n, not requiring 
COV ID-related c are; 3, hospi[INVESTIGATOR_36515], not requiring supplemental 
oxygen;  4, hospi[INVESTIGATOR_057], requiring supplemental oxygen;  5, 
hospi[INVESTIGATOR_057], requiring nasal hi gh-flow ox ygen t herapy, 
noninvasive mech anical ventilation, or both ; 6, hospi[INVESTIGATOR_057] , 
requiring ECMO, in vasive mecha nical ventilation,  or both; and , 
7, death.  
• Change in biomarker  levels  (CCL 5, IL-6, Chi311 , etc) from time 
of enrollment  to completion of therapy  or live discharge  from  the 
hospi [INVESTIGATOR_307] (whichever comes first)   
• 7-, 14- and 28-day all -cause -mortality   
• Days on mechani cal ventilati on 
SAFETY 
EVALUATIONS  Daily, multi -disciplinary safety monitoring  with interi m analysis after 
[ADDRESS_617705] 
recei ved more than four doses of treatment. Serious adverse events 
will be monitored by [CONTACT_480703].  
  STATISTICS  
Analysis Plan  • Rates o f adverse eve nts by [CONTACT_480704].   
• Change in biomarker s compared to clinical improv ement  
•  Percent of study population reaching clinical improvement at 
Day 7 will be compared to published results from Remde sivir 
for 5 or 10 Da ys in Patient s with Severe C OVID -19, and other 
available clinical trials including The Randomized  Evaluation 
of COVID -19 therapy ( RECOVERY) Trial . 
 
Protocol : Open -Label Study  of Maraviroc in Hospi[INVESTIGATOR_480676] s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/[ADDRESS_617706]  ................................ ................................ .......................  12 
8.3 Supply of Study Medication at the Site  ................................ ................................ ....... 12 
8.4 Study Medication Accountability  ................................ ................................ ...............  13 
8.5 Measures of Treat ment C ompliance ................................ ................................ ...........  14 
9 STUDY PROCEDURES AND GUIDEL INES ................................ ................................ . 14 
9.1 Clinical  Assessments  ................................ ................................ ................................ ... 14 
9.2 Clini cal Laboratory Measurements  ................................ ................................ .............  15 
9.3 Research Laboratory M easurements  ................................ ................................ ...........  15 
10 EVAL UAT IONS BY [CONTACT_16990]  ................................ ................................ ...............................  16 
10.1 Screening/Enrollement  (Day  0) ................................ ................................ ...................  16 
10.2   Visit 1 (Day 1) ................................ ................................ ................................ ............  16 
10.3 Visit 2 (Day 2) ................................ ................................ ................................ .............  16 
10.4 Visit 3 (Day 3) ................................ ................................ ................................ .............  17 
10.5 Visit 4 (Day  4) ................................ ................................ ................................ .............  17 
10.6 Visit 5 (Day 5) ................................ ................................ ................................ .............  17 
10.7 Visit 6 (Day 6) ................................ ................................ ................................ .............  18 
10.8 Visit 7 (Day 7) ................................ ................................ ................................ .............  18 
10.9 Visit  8 (Day 8) ................................ ................................ ................................ .............  18 
10.10   Visit 9 (Day 9) ................................ ................................ ................................ ..........  [ADDRESS_617707]-Intervention Follow -up (Day 10 and  after till discharge)  ................................  19 
Protocol : Open -Label Study  of Maraviroc in Hospi[INVESTIGATOR_480676] s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/[ADDRESS_617708]-Discharge Follow -up (perform every 3 days till Day 28)  ................................ . 19 
10.14   Final Visit  (Day 28) ................................ ................................ ................................ .. 19 
10.15   Early Withdrawal Visit  (In-hospi[INVESTIGATOR_307])  ................................ ................................ ........  19 
10.16   Early Withdrawal Visit  (Out-of--hospi[INVESTIGATOR_307])  ................................ ................................  20 
10.17   Death  ................................ ................................ ................................ .........................  20 
11 ADVERSE EXPERIENCE REP ORTING AND DOCUMENTA TION  ........................  20 
11.1 Adve rse E vents  ................................ ................................ ................................ ...........  20 
11.2 Serious A dverse E xperiences (SA E) ................................ ................................ ...........  21 
11.3 Medical Monitori ng ................................ ................................ ................................ .... 22 
12 DISCONTIN UATIO N AND REPLACEMENT OF SUBJECTS ................................ ... 22 
12.1 Early Discontinuation of Study Drug  ................................ ................................ ..........  22 
12.2 Withdra wal of Subjects  ................................ ................................ ...............................  22 
12.3 Replacement of Subjects  ................................ ................................ .............................  23 
13 PROTOCOL VIOLATI ONS  ................................ ................................ .............................  23 
14 DATA SAFETY MONITORI NG ................................ ................................ ......................  24 
14.1 Postura l Dizziness and Orthosta tic Hypotension  ................................ .................  24 
14.2 Cardiac Event s ................................ ................................ ................................ ..........  26 
14.3 Hepatotoxicity  ................................ ................................ ................................ ...........  26 
14.4 Other  Adver se Events  ................................ ................................ ................................ . 27 
14.5 Unan ticipated Adverse  Events  ................................ ................................ ....................  27 
15 STATISTI CAL METHODS AND  CONSIDER ATIONS  ................................ ...............  27• 
15.[ADDRESS_617709] Confidentiality ................................ ................................ ................................  29 
17 ADMINISTRATIVE, ETHI CAL, REGULATORY CONSIDER ATIONS  ..................  29 
17.1 Protocol A mendments  ................................ ................................ ................................ . 30 
17.2 Institution al Revi ew Bo ards and Indepe ndent Ethics Committees  .............................  30 
17.3 Informed Consent Form  ................................ ................................ ..............................  30 
17.4 Publications  ................................ ................................ ................................ .................  31 
 
Protocol : Open -Label Study  of Maraviroc in Hospi[INVESTIGATOR_480676] s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 7 of 30 
 1 BACKGROU ND 
Severe Acute Respi[INVESTIGATOR_13521] y Syndrome Coronavirus 2 (SARS -CoV -2) is the c ause of 
Coron avirus  disease  2019 (COVID -19) and was first reported in Wuhan, China in 
December [ZIP_CODE]. Though a wide spectrum of clinical manifestations exists, p atients often 
present w ith mi ld upper respi[INVESTIGATOR_23908], progressing in some cases to a mult ifocal 
pneumo nia wi th multi organ compromise2. As the  natural history of SARS -CoV -[ADDRESS_617710] been as sociated with increased mortality3. 
In the negative randomized, controlled, open -label trial of Lopi[INVESTIGATOR_054] -Ritonavir 
involving patien ts with  COVID -19 and oxyg en saturation of less than 94% on room air, 
70% of pa tients required suppl emental  oxygen and 15% required high -flow nasal cannula 
or non -invasive mechanical ventilation on  presentation. Only one patient required 
intubation on prese ntation, but 16%  would ev entually require mechanical ventilation during 
their hospi[INVESTIGATOR_1916]. At D ay 7, only 6% of the subjects  in the Lopi[INVESTIGATOR_054] -Ritonavir  reached 
clinical impro vement of 2 points on a 7 -point ordinal scale . At day 14, 45.5% of subjects 
reached 2-point clini cal im provement, 15.2% of subjects had died , and 28% continu ed to 
require non -invasive and nasal cannula support.  This early  study highlight ed the length y 
duration  of hospi[INVESTIGATOR_480682] D-19. 4 
SARS-CoV -2 is a n RNA coronavirus  that enters the cell through an en dosomal 
route , during which  the virus attaches  to Angiotensi n-Converting -Enzyme -2 receptor , 
subsequently endocytosed  into a vesi cle and released into the c ytoplasm o f the cell via 
cathepsin -cleav ed spi[INVESTIGATOR_144870] . The viru s can also attach to Transmembrane Serine 
Protea se 2 (TMPRSS2)  to directly enter the cell  via fusion  with the cell membrane. Once in 
the cell the viral mRNA is transcribed  via RNA -dependent RNA polymerase  to create  more  
 
1 Li Q, Guan X,  Wu P, et al. Early  Transmission Dynamics in Wuhan, C hina, of Novel Corona virus–Infected 
Pneumonia. N Engl J Med. 2020;382(13):1199 -1207. doi :10.105 6/NEJMoa2 001316 
2 Huang C, W ang Y, Li X,  et al. Clinical features of patients infected with 2019 novel coronavirus in W uhan, 
China. Lancet. 2020;3 95([ZIP_CODE]):497-506. doi:10.101 6/S0140 -6736(20)[ZIP_CODE] -5 
3 Zhou F, Yu T, Du R, et al. Clinical course and  risk factors for mortality of adult inpatients with COVID-19 
in W uhan, China: a retrospective cohort study. Lanc et. 2020;395([ZIP_CODE]):1054-1062. doi :10.101 6/S0140-
6736(20)[ZIP_CODE] -3 
4 Cao  B , Wang  Y, Wen  D,  et al.  A trial of lo pi[INVESTIGATOR_054] -riton avir in adul ts hospi[INVESTIGATOR_249122] -19 
N Engl J Med. 2020. doi:10.1056/NEJ Moa2001282  
 
Protocol : Open -Label Study  of Maraviroc in Hospi[INVESTIGATOR_480676] s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 8 of 30 
 genome RNA. Additionally , sub-genom ic mRNA s are translated to create proteins 
including proteases  and replicates , such  as papain -like pro tease, 3C -like pro tease (also 
known as main protease) and  RNA -dependent  DNA polymerase (RdRp) . 5These proteins  
serve a s potential targets for anti -virals. Remdesiv ir, an anti -viral that rece ived FDA 
Emer gency Use Auth orization for use in COVID -19, targets RdR p. Other FDA approved 
medications  have b een identified as potential drugs to re-purposing.  Virtual screenin g of 
2388 FDA approved medications for binding affini ty to the SARS -CoV -2 3C-like protease 
(main protease ), which is essential  for processing t he polyproteins require d for viral 
assembly , revealed  the CCR5 -antognist Maraviroc  to have the second -highest binding 
affinity. Further  molecular  conformational  dynamic sim ulations and the MMPB SA 
approach a re ongoing to provide further estimation of the binding affinity of Maraviroc to 
binding site on the 3C-like protease.[ADDRESS_617711] essing the com plex pathop hysiology un derlying 
COVID -19 inf ections t o better understand  human respon ses to the nov el coronavirus . 
Given the similarit ies betwe en other coronaviruses, including  SARS -CoV -1, and S ARS -
CoV -2, pathogenes is of SARS -CoV -2 has been  extrapolated fr om SARS -CoV -1 disease in 
animal models . In senescent mouse models of SAR S-CoV -1 infec tion, increase d 
expression of chemokine mRNA was observed in the lungs early and late in the infection, 
in a “biphasic ” manner. Compared to cont rols, a >9-fold increase in  CCL5/RANTES and [ADDRESS_617712] itic ce ll chemotaxi s.9    
  
 
5 Simmons G , Zmora P,  Gierer S, Heurich A, Pöhlmann S. Proteolytic activation  of the SARS -coronavirus 
spi[INVESTIGATOR_144870]: cutting enzymes at the cutting  edge of anti viral research. Antiviral Res. 2013;100(3):605 -614. 
doi:10.1016/j.antiviral.2013.09.028  
6 A. Shamsi, T. Moh ammad, S. Anwar, F. MohamedAl  Ajmi, A. Hussain, M.T. Rehman, A. Islam, M.I.  
Hassan  Glecaprevir and Maraviroc are high -affinity inhibitor s of SARS -CoV -2 main protease: possible 
implication in COVID -19 therapy . Bioscience Reports , 40 (2020)  10.1042/BSR202012 [ADDRESS_617713] ome 
Coronavirus (SARS-CoV) Infecti on in Senescent BALB/c Mice: CD4+ T Cells Are Important in Control of 
SARS-CoV Infection.  J Virol. 2010; 84(3):1289-1301. doi:10.112 8/jvi.[ZIP_CODE] -09 
8 Grommes J, Drechsler M, Soehnlein O. CCR 5 and F PR1 me diate neutrophil recruitment in endo toxin-
induc ed lung injury. J Innate Immun. 201 4;6(1):111-116. doi:10.1159/[ADDRESS_617714] maraviroc on ch emotactic activity of mono cytes, macrophages and den dritic cells. Clin Exp 
Immunol. 2011;1 66(2):184-190. d oi:10.1111 /j.1365-2249.2011 .[ZIP_CODE]. 
Protocol : Open -Label Study  of Maraviroc in Hospi[INVESTIGATOR_480676] s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 9 of 30 
 Chitinase 3 -like 1 (Chi3l1, also called as YKL -40) is a powerful inhibitor of 
epi[INVESTIGATOR_480683]. Mice that lack Chi3l1 are par ticularly 
susceptible to the ravages induced by [CONTACT_480705] t induce Acute 
Lung Injury (ALI).[ADDRESS_617715] demonstrated that the expression levels of Chi3l1 in the 
lung were significantly decreased by [CONTACT_480706] -like helicase (RLH) immun e activation, the 
well-defined host sensing mechanism of RNA viruses lik e SARS -CoV -2.[ADDRESS_617716] of infl ammatory  mediator expre ssion may  reverse 
lympho id depletion a nd may alter cell trafficking of inflammatory cells, bo th increasing 
viral control capac ity and d ampening damage to lung tissue, respectively .  
2 STUDY RATIONA LE 
This pi[INVESTIGATOR_480684] R5/CCL5 axi s as well 
as the potential anti -viral pro perties of Maraviroc  may redu ce disease severity.  This proof -
of-concept effo rt seeks to correlate differences in clinical outcomes t o differential cy tokine 
expression in the setting  of CCR5 antagon ism in patients infe cted with SARS -CoV -2. 
Maraviroc is FDA -approve d for the treatment of  CCR5 -tropi c HIV-[ADDRESS_617717] regression protein -39 and YKL -40 regulate hyperoxia -
induced  acute lung injury. Am J Respir Crit Care Med 182, 918 -928 (2010).  
11 B. Ma et al ., RIG -like Helicase Regulation of Chitinase 3 -like 1 Axis and Pulmonary Metastasis. Sci Rep 6, 
[ZIP_CODE]  (2016 ). 
12 Vourvahis M, Fang  J, Ch ecchio T, et al. Pharmacokinetics, safety, and tolerability of maraviroc in HIV-
negative subjects with impaired renal function. HIV Clin Trials. 201 3;14(3):99-109. doi :10.131 0/hct1403-99 
 
Protocol : Open -Label Study  of Maraviroc in Hospi[INVESTIGATOR_480676] s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 10 of 30 
 3.2 Secon dary Objective s 
The secondary  objective is to investigate the  relationship between reduction o f 
inflammatory markers (such as IL -6, CCL5, etc.) and clinical outcomes , including 
avoidance of respi[INVESTIGATOR_696] d ecompensation  and death . 
[ADDRESS_617718] blood samples checked at time of enrollm ent (Day 0), Day 3, Day 7, and 
Day 1 5 or time of live discharge (whic hever comes f irst) of the  study. The total duration of 
subject participation  will be five weeks . The total duration of the study is expected to be 1 6 
weeks.  
5 CRITERIA FOR EVALUATION  
5.1 Primar y Endpoint  
This proof -of-conce pt trial will evaluate  safety  and toler ability of Ma raviroc in SARS -
CoV-2 infected patients. The primary endpoint i s rate of pati ents who complete the 7-day 
course of Maraviroc  without discontinuation for ad verse event s, hospi [INVESTIGATOR_059],  or death.    
Additional  endpoints include t he percent of s tudy populati on reaching clinical 
improvement , defined as t ime fro m enrollment  to an improvement of two  points on a 
seven-category ordinal scale  (defined below) , at Day 7. 
5.2 Secondary Endpo ints 
• Time to clinic al improvement , defined as time fro m enrollm ent to an improveme nt of 
two points on a seven-category ordinal scale  (defined below)  or live discharge f rom 
the hospi[INVESTIGATOR_307] , whichever  comes first  
o Ordinal scale : 1, not hospi[INVESTIGATOR_480685]; 2, not 
hospi[INVESTIGATOR_057], but un able to r esume no rmal activiti es OR hospi[INVESTIGATOR_18552] d pending 
dispositio n, not requiring COVID -related care ; 3, hospi[INVESTIGATOR_057], not requiring 
suppleme ntal oxygen;  4, hospi[INVESTIGATOR_057], re quiring supplemental oxygen;  5, 
hospi[INVESTIGATOR_057], requiring nasal high -flow oxygen therapy, no ninvasiv e 
ventilation , or both ; 6, hospi[INVESTIGATOR_057] , requiring ECMO, invasive mechanical 
ventilation, or both; and , 7, death.  
• Change in cytokine  levels  from ti me of enrollment  to completion of therap y or live 
discharge  from the hospi[INVESTIGATOR_307] (whichever comes first)   
• 7-, 14- and 28-day all-cause -mortali ty  
• Time to improvement to Score of 2 or less ( days) 
• Days on mechanical ventilation  
 
Protocol : Open -Label Study  of Maraviroc in Hospi[INVESTIGATOR_480676] s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/[ADDRESS_617719] ION  
6.1 Study Populati on 
Subjects with a diagnosis of SARS -CoV -2 who meet the inclusion criteria w ill be elig ible 
for p articipation  in this stud y.   
6.2 Inclusion Cr iteria  
• Male or female ≥ 18 years of age at time of screening    
• Documentation of a SA RS-CoV -2 diagnosis as evidenced by [CONTACT_95570] S ARS -CoV -2 
PCR within twelve  days at time of screening  
• Chest  radiography co nsistent w ith multi -focal pneumonia or air -space disease  
• Written informed consent obtained from  subject  and ab ility for subject to comply 
with the requirements of the study.  
• Subject able to safely swal low pi[INVESTIGATOR_480686]  a nasogastric or  
orogastric tube.  
6.3 Exclusion Criteria  
• Subjects who are p regnant , breastfeeding, or unwilling to prac tice birth  control du ring 
partic ipation in the study.  
• Subjects with the p resence of a condition or abnormali ty that in the opi[INVESTIGATOR_1101] t he 
Investigator s would compromise the safety  of the subject  or the quality of the da ta. 
This includes, but is not limited to, recent  myocardial  infarction  in past 6 months, 
neurological, psychiatric, endocrine, or neoplastic disea ses that ar e judged to inte rfere 
with particip ation in the study.  
• Subjects with known diagnosis of human immun odeficiency virus infection (HIV)  
• Subjects enrol led in anot her interve ntional trial (including one for COVID -19) that 
excludes participation in ot her trials,  or includes a p otent CYP3A inhibit or of inducer  
(e.g. lopi [INVESTIGATOR_054] -ritonavir)  
• Subjects with ESRD or severe renal failure who are taking po tent CYP3A  inhibitors  or 
inducer s 
7 CONCURRENT MEDICATIONS  
7.1 Allowed Medications and Treatments  
Diligent m edicatio n reconciliat ion will be performed between the primary inpatient team  
and study team. Reduction in dose or d iscontinuation of CYP3A inducers/inhi bitors, an ti-
hypertens ive medication s, and diuretics at ti me of  enrollment will be considered and 
individuali zed to each subject at the discretion of the inpatient team.  Remdesivir  and 
dexamethasone , if administered out side o f a clinical trial, are allowed.  
 
Protocol : Open -Label Study  of Maraviroc in Hospi[INVESTIGATOR_480676] s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 12 of 30 
 7.2 Prohibited  Medications and Treatments  
The following medications a re proh ibited during the study and adminis tration w ill be 
consid ered a protoc ol vio lation.   
• Lopi[INVESTIGATOR_054] -Teno fovir  
• Hydroxychloroquine  
• Ivermectin  
[ADDRESS_617720] been diagnosed with S ARS -CoV -2 and agree to 
partic ipation in the stud y will be placed on Maraviroc 30 0 mg twice daily for 7 days.  
Given design as an early, p roof-of-concept trial, all patients  will be a ssigned to the 
treatment group. The re will b e no placebo co ntrol group; ho weve r, patients  who are 
withd rawn from  the trial  drug will be consented at time of enrol lment  about cont inuing 
biomarker surveillance  at standard scheduled monitor ing times (Day  0, 3, 7 and the earlie r 
occurring  timepoin t of disc harge or Day 15). Subjects  who stop Maraviroc prior to 
completion of Maraviroc  will not be replaced .  
By [CONTACT_29286], Day [ADDRESS_617721] y of Study Drug at the Site  
[COMPANY_007] will  reimburse for s tudy drug obtained by  [CONTACT_480707].   
8.3.1 Dosage/Dosage Regimen  
• Maraviroc 300 mg  twice a day fo r patients n ot on concomitant  moderate or  
strong CYP3A inhibitors/inducers.  
• Maraviroc 150 mg twice daily  for patients unable to  tolerate 3 00 mg twice daily 
and for patients on moderate or strong CY3PA inhi bitors.  
• Maraviroc [ADDRESS_617722]  at the t rial site.  
Protocol : Open -Label Study  of Maraviroc in Hospi[INVESTIGATOR_480676] s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/[ADDRESS_617723] protocol  
of the inpatient unit . 
8.4 Measures of Treatme nt Compliance  
Medication Administration re cords from  site’s Electron ic Medical Record will be a udited 
daily to ensure tr eatment compliance.  
9 STUD Y PROCE DURES A ND GUIDELINES  
Prior to conduc ting any study -related activit ies, written informed consent and the Health 
Insura nce Portability and Accountab ility Ac t (HIPAA) au thoriz ation must be signed and 
dated by [CONTACT_3433] e subject .  
9.1 Clinical Assessments  
9.1.1 Concomit ant Med ication s 
All concomitant medication and concurrent therapi[INVESTIGATOR_480687] /Enrollment  Visit (Day 0), during  Study Days 1 -8, and at early  terminati on when 
applicable.  Do se, rou te, un it frequency of administration, and indic ation f or adminis tration 
and d ates of medication will be captured.  
9.1.2 Demographics   
Demographic information (date of birth, gen der, race)  will be recorded a t enrollment .  
9.1.3 Medical His tory  
The fol low will be recor ded at  Screening :  
• Date of onset and presence of sympt oms relate d to SARS -CoV -2 infection 
including  cough, sho rtness of breath,  fatigue, nausea, vomiting, dia rrhea, rash, 
abdominal pain, fever, chill s, loss of smell, etc.  
• Histor y of obesity, hemodi alysis , cardio vascular diseases (hyp ertension, known 
valvu lar disease, ca rdiomyopat hies an d/or L V systolic or diastolic dy sfunction), 
pulmonary disease (i ncluding OSA , COPD, asthma, inters titial lung disease, c ystic 
fibrosi s, bron chiect asis, lung transplan t, lun g cancer , pulmonary hypertensi on).  
9.1.[ADDRESS_617724] igators may perform an abb reviated  physical exam at each  visit and utilize 
components of the physical e xam per formed by a qualified  staff member  (MD, N P, and 
PA) on the primary care team .   
Protocol : Open -Label Study  of Maraviroc in Hospi[INVESTIGATOR_480676] s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/[ADDRESS_617725] to do so ( e.g. patient 
requiring sub stantial amount of supplemental oxygen ).  
9.1.7 Other Clinical Procedures  
• Imaging obtained as par t of routine clinical care with be revie wed.  These will 
include  chest -imaging and CT imaging.   
• Thromboelast ography, if obtained part of routine  care will also be  review ed and 
documented . 
9.1.[ADDRESS_617726] ’s room . Appropriate documentation in case repo rt 
forms will reflect subjects who are un able to participate in conversation  due to altered 
mental status o r mechanical ventilation . In addition , all clinica l documentation obtained by 
[CONTACT_75462] , as per clinical policy and  standard s of care, will be reviewe d daily for 
informati on pertaining to  adver se events . Duration (start and s top dates and times), 
severity/g rade, outcome, treatment,  and relation to stu dy drug will be recorded on the case 
report form (CRF)  as detailed in  Section [ADDRESS_617727]  of care  and sen t to trial site ’s hematology lab  for a 
complete blood count (hemoglobin, hema tocrit, red blood cell count, white  blood cell 
count, white blood cel l differential  including absolute n eutrophil cou nt, abs olute bands, 
absolute  lymphocyte count)  and pl atelet co unt) , serum C -reactive protei n (CRP ) and 
thromboelastography .  
9.2.[ADDRESS_617728] of care an d sent to trial site’s chemistry l ab for 
determ ination  of  serum so dium, potassium , chlori de, bicarb onate,  random glucose, BUN, 
creatinin e, aspa rtate aminotransfer ase (AST/SGOT ), alanine aminotransfe rase 
(ALT/SGPT), alkali ne phosphatase,  total bilirubin, direct bilirubin, albumin , LDH , brain 
natriuretic peptide (BNP), D-dimer, troponin and lactate.  
Protocol : Open -Label Study  of Maraviroc in Hospi[INVESTIGATOR_480676] s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/[ADDRESS_617729] of   sCD40L, GM -CSF, IF N 
gamma, IL -2, IL -4, IL -6, IL -8, IL -10, RANTS, TNF -alpha, and VEGF . Using PB MCs, 
InCellDx will also perform a CCR 5 Receptor occupancy analysis.  If enough plasma and 
PBMC samples are banked, banked samples will be sent to the The Prli c Lab at the Fred 
Hutchinson Cancer Cen ter near the end of the study . The Prlic Lab will perform  additional  
flow cytometric anal ysis to provide insight regarding the immune  subset distribution and 
state of activation  of the immune system.  Additionally, up to three 100 ul alliqots of banked 
plasma will be sent to  The El ias Lab at Brown University , who will pe rform analysis on  
Chitinase  3-like 1 (Chi3l1 ) at the end of the study  period . Remainin g specimen will be 
stored at InCellDx  for up to six months after th e end of the study , during which 
arrangements will be made to return remaining specime n to Lifespan /The Miriam Hospi[INVESTIGATOR_480688] C enter . Remaining specimens will be destroyed 5 
years after return to Lifespan . Until that time, t hese remaining specimens  may be  used for 
validation of results or may be used for further  research  studies.      
10 EVALUATIO NS BY [CONTACT_16990]  
10.1 Screenin g and Enrol lment Vi sit (Day  0) 
• Review the study with the subject  and obtain w ritten informed consent  
• Assign the subject a  unique subject  number . 
• Record demographic s data.  
• Recor d relevant medica l history . 
• Record  concomitan t medications.  
• Perform  a complet e physical examination.  
• Perform a complete review o f systems including symptom s of postural  dizziness  
• Perfor m and record v ital signs.  
• Perform and record oximetr y on r oom air and o n curr ent oxygen -deliverin g device . 
• Perform a nd re cord results of b lood pressur e testing , including orthostatic vital 
signs . 
• Document and review blo odwo rk obtained from standard  clinical care (chemis try, 
hematology,  hepa tic function) . 
• Collect blood sample for research  laborator y test (s):  Biomarkers . Collect 
information on QTc i f an electro cardiogram  is performed per rout ine clinical care . 
• Document and rev iew chest imaging  findings if  perfor med per routine clinical car e. 
Protocol : Open -Label Study  of Maraviroc in Hospi[INVESTIGATOR_480676] s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 16 of 30 
 10.2 Visit 1 (Day  1) 
• First dos e of Ma raviroc Administered  in morn ing. Study member will be prese nt for 
first administrat ion 
• Perform interview with patient. Docu ment any Adverse Even ts. 
• Document c omplete  physical exam . 
• Perform and document  medications review . 
• Perform and record vital signs . 
• Perform and record oxi metry on room air and  on current oxygen -delivering d evice.  
• Reco rd any events including  transfer to intensive care, intubation , hospi[INVESTIGATOR_6125] r eferra l. 
• Document laboratory  values  and imaging  obtai ned as part of  routine standard o f 
care. 
10.3 Visit 2 (Day  2) 
• Review and  document Medication Administration Record for Day  1 of study . 
• Perform interview with patient. Recor d any Adverse Events.   
• Document  complete  physical exam . 
• Perform and record vital signs . 
• Perform and rec ord oximetry on room air and on c urren t oxygen -delive ring device.  
• Record any events inclu ding transfer to intensive care, intubation, hospi[INVESTIGATOR_480689] . 
• Document laboratory  values  and imaging  obtai ned as part of routine standard o f 
care. 
10.4 Visit 3 (Day  3) 
• Review and document Medicat ion Admin istration Record  for Day 2 of study . 
• Perform interview with  patient. Record any Adv erse Events.   
• Document c omplete  physical ex am. 
• Perform and record vital si gns. 
• Perform and record oximetry on room air and on current oxygen -delivering de vice.  
• Record any ev ents inc luding trans fer to intensive care, intubation, hosp ice referral . 
• Document laboratory  values  and imaging  obtai ned as part of routine standard o f 
care. 
• Collect blood sample for research  laborator y test (s):  Biomarkers . 
 
Protocol : Open -Label Study  of Maraviroc in Hospi[INVESTIGATOR_480676] s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 17 of 30 
 10.5 Visit 4 (Day 4) 
• Review and document Medication Adm inistration Record  for Day  3 of study . 
• Perform interview with p atient. Record any Adve rse Events.  
• Document c omplete  physical e xam. 
• Perform and record vital signs . 
• Perfo rm and recor d oximetry on room air and on c urrent oxygen -delivering device.  
• Record any e vents including  transfer to intensive c are, intubation, hospi[INVESTIGATOR_480689] . 
• Document laboratory  values  and imaging  obtai ned as part of rou tine standard o f 
care. 
10.6 Visit 5 (Day 5)  
• Review and document Medication Administration Record  for Day  4 of study . 
• Perform interview with p atient. Recor d any Adverse Events.   
• Docu ment c omplete  physical exam . 
• Perform and record vit al signs . 
• Perform and record oximetry on ro om air and on current oxygen -delivering  device.  
• Record any events including  transfer to intensi ve care, intubat ion, hospi[INVESTIGATOR_480690]. 
• Document laboratory  values  and imag ing obtai ned as part of routine standard o f 
care. 
10.7 Visit 6 (Day 6 ) 
• Review and document Medication Ad ministration Record  for Day  5 of study . 
• Perform interview with pat ient. Record any Adverse Events.   
• Docum ent c omplete  physical exam . 
• Perform and record vita l signs . 
• Perform and record oximetry on room air an d on current  oxygen -delivering device.  
• Reco rd any events including  transfer to intensive care, intubation, hospi[INVESTIGATOR_480691]. 
• Document laboratory  values  and imaging  obtai ned as part of routine standard o f 
care. 
10.8 Visit 7 (Day 7) 
• Review and document Medication Administrat ion Record  for Day  6 of study . 
• Perform interview with patient. Record any Adverse Events.   
• Document c omplete  physical exam . 
Protocol : Open -Label Study  of Maraviroc in Hospi[INVESTIGATOR_480676] s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 18 of 30 
 • Perform and record vita l signs  
• Perform and record oximetry  on room ai r and  on current oxygen -delivering device.  
• Record any ev ents includi ng transfer to intensive care, intubation, hospi[INVESTIGATOR_480692] l. 
• Document laboratory  values  and imagi ng obtai ned as part of routine standard o f 
care. 
• Collect b lood sample f or research  laborato ry test (s):  Biomarkers  
10.9 Visit 8 (Day 8) 
• Review and document Medication Administratio n Record  for Day  7 of study . 
• Perform interview with patie nt. Record any Adverse Events.   
• Document c omplete  physical exam . 
• Perform and record vital signs  
• Perform and record oximetry on room air and  on current o xygen -delivering device.  
• Record a ny event s including  transfer to intensive care, intubati on, hospi[INVESTIGATOR_480693]. 
• Document laboratory  values  and imaging  obtai ned as part of routine standard o f 
care. 
10.[ADDRESS_617730]-Intervention Follo w-up (Day [ADDRESS_617731] day  prior to  discharg e) 
• Perform  interview with patient . Record any Adve rse E vents.   
• Perform and record vital signs . 
• Perform and record oximetry on  room  air and on current  oxygen-delivering device.  
• Record any event s includin g hospi[INVESTIGATOR_1838], intubation, intens ive-care admission . 
• Document  laboratory  values  and imaging  obtai ned as part of routine standard o f 
care. 
• Obtain blood  sample s for research  laboratory test  on Day 1 5 
10.11  Day of Di scharge  
• Perform interview with patient . Record any Adverse E vents.   
• Perform and r ecord vital signs . 
• Perform and record oximetry on r oom air a nd on current  oxygen -delivering device.  
• Document laboratory  values  and imaging  obtai ned as part of routine standard  of 
care. 
• Record discharge destination , oxygen req uirement at time of discharge . 
• Obtain research  labwork  if discharge occurs earlier than Day 1 5 
Protocol : Open -Label Study  of Maraviroc in Hospi[INVESTIGATOR_480676] s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 19 of 30 
 • Schedule p ost-discharg e phone follow -up. 
10.[ADDRESS_617732]-Dischar ge Follow -up (perform weekly  till Day 35) 
• Perform phone i ntervie w with patient. Rec ord any Adverse Events.  
• Revi ew and document h ome medications . 
• Review and document pat ient acquired vitals . 
• Record any eve nts including h ospi[INVESTIGATOR_059],  intubati on, inten sive-care adm ission . 
10.13   Final Vi sit (Day 35) 
• Inform subject thi s will be the final visit of the study . 
• Perform interview with patient. Record any Adverse Events.  
• If in hospi[INVESTIGATOR_307] , record findings from abbreviated  physical  examination.  
•  If in hospi[INVESTIGATOR_307] , perform and reco rd vital signs .  
• If in hospi[INVESTIGATOR_307] , perform and re cord oximetry  on room air and on current oxygen -
deliv ering device.  
• If in hospi[INVESTIGATOR_307], document laboratory  values  and imaging  obtai ned as part of routine 
standard o f care . 
• If in hospi[INVESTIGATOR_307] , record  any events including intubation, intensive -care adm ission, 
change to comfort m easures, hospi[INVESTIGATOR_480694] . 
10.14   Early Withdrawal  Visit (In-Hospi[INVESTIGATOR_307])  
• Review  and document Medication Administra tion Record . 
• Perform a nd record vital sig ns, including orthos tatic vital signs . 
• Perform and record oximetry on room a ir and on curre nt oxy gen-delivering devi ce. 
• Document laboratory  values  and imaging  obtai ned as part of routine standard o f 
care. 
• Assent to collect blood sample f or clinical laboratory t ests:  Biomarke rs at Day 3 
and Day 7. 
• Record any events including intubation , intensive -care admission , chang e to 
comfor t measures,  hospi[INVESTIGATOR_480694] . 
10.15   Early Withdrawal  Visit  (Out-of-Hospi[INVESTIGATOR_307] ) 
• Review and document home m edications . 
• Review an d doc ument pat ient acquired vi tals. 
• Document  subjects ’ current location of care type (e.g.  acute rehabilit ation  center) . 
Protocol : Open -Label Study  of Maraviroc in Hospi[INVESTIGATOR_480676] s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 20 of 30 
 • Record any events i ncluding intubation, intensiv e-care admission , change to 
comfort measures, change to do not hos pi[INVESTIGATOR_18552] ( DNH) , hospi[INVESTIGATOR_480695] t ransfer. 
10.16   Death  
• If in hospit al, review  and document Medication Administration Record. Document 
laboratory  values  and imaging  obtai ned as part of routine standard o f care . 
• Revi ew and docum ent time and cause of death . 
• Inform IRB of subject  death . 
• Record any preceding events including hospi[INVESTIGATOR_059] , intubation, intensive -care 
admission , change to co mfor t measure s, hos pi[INVESTIGATOR_480694] . 
 
11 ADVERSE EXPERIENCE REPORTING AND D OCUMENTATION  
11.1 Adverse Events  
An adverse event  (AE) is any untowa rd medical occurrenc e in a clin ical investigation of a 
patient administ ered a pharmaceutical produc t and does not ne cessarily have a causal 
relationship with the treatment.  An AE is there fore any unfa vorable and un intended sign 
(includi ng an abnormal labo ratory finding), sym ptom o r disease temporally associated with 
the administration of an invest igational product, whe ther or not  it is related to that 
investigational product.  An unexpected AE i s one of a ty pe not identif ied in nature, 
severity, or frequen cy in the current In vestigator’s  Brochure or of greater severity or 
frequency than expected based o n the inf ormat ion in the In vesti gator’s Bro chure.  
The study team  will probe, via discussion wit h the subject , for the occu rrence of AEs 
during each subject encounter and record the informat ion in the site’s source documents.  
Adverse events will be recorde d in the patie nt case-repor t form.  Adverse  events will be 
described by [CONTACT_24109] (start and sto p dates and t imes), severit y, outcome, treatment,  and 
relation to study drug, or i f unrelated, the cause.  
AE Severity  
The National Canc er Institute’s Common Term inology Criteria for Adverse E vents 
(CTCAE)  Version 4.0 should be used to assess and grade AE se verity, inclu ding laboratory  
abnormalities  judged to be  clinic ally significant. Only for the specific Adverse Event of 
change in l iver enzymes will The National  Canc er Institute ’s Common Termin ology 
Criteria for Adverse E vents (CTCAE) Version 5.0 be used.  If the experience is not covered 
in the mo dified cr iteria, the  guidelines shown i n Table 2 below should be used to grade 
severity.  It should be pointed out tha t the term “sever e” is a measure of intensi ty and that a 
severe  AE is not necessarily serious.  
Protocol : Open -Label Study  of Maraviroc in Hospi[INVESTIGATOR_480676] s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 21 of 30 
 Table 2.  AE Severity Grad ing 
Severity (Tox icity Grade)  Descrip tion 
Mild (1)  Tran sient or mild discomfort; no limitation in activity; no medical 
intervention or  therapy required . The subj ect ma y be aware  of the sign 
or symp tom but tolerates it reasonably w ell. 
Moderate (2)  Mild t o moderate limita tion in activ ity, no  or minimal medical  
interven tion/therapy required.  
Severe (3)  Marked limitation in activity, medi cal inter vention/ therapy re quired , 
hospi[INVESTIGATOR_11298] s possible.  
Life-threaten ing (4)  The subject is at risk of death due t o the adverse exp erience as it  
occurr ed. This does not r efer to a n experience that hypothetically 
might have caused death if it were mo re severe . 
 
AE R elationshi p to S tudy Drug  
The relationship of an AE to the study drug should be  assessed using the follo wing the 
guidelin es in Table 3. In delineating AE relationship, research team will consider a dverse 
events tem porally or other wise clear ly related to administration of the drug in relation to 
noted deviation from natural history of  SARS -CoV -2 infectio n. 
Table 3.  AE Rel ationship to Study Drug  
Relationship  
to Drug Comment  
Definitely  Previously kno wn toxicity of ag ent; or an ev ent that foll ows a reasonable temporal 
sequence from admin istratio n of the drug; that fo llows a  known or exp ected response 
patte rn to the suspected  drug; that i s confirmed by [CONTACT_13635][INVESTIGATOR_480696]; and th at is not ex plain ed by [CONTACT_480708].  
Probably  An event that follows a reason able temporal sequence  from a dministration  of the 
drug; that f ollows a k nown or e xpected respo nse pattern to the suspected drug ; that is 
confirme d by [CONTACT_13635][INVESTIGATOR_007] o r reducing t he do sage of the d rug; and that  is unlikely to be 
explained by [CONTACT_480709]’s clinica l state or by  [CONTACT_41847] . 
Possibl y An even t that follow s a reasonable temporal sequence from administratio n of the 
drug; that follows  a known or expect ed response p attern to that suspected drug; but 
that could  readily  have been produced by  a numb er of other f actors.  
Unrelated  An event th at can be  determined w ith certainty to have no relation ship to the study 
drug.  
11.2 Serious Adverse Expe rienc es (SAE)  
An S AE is defined  as any AE occurring at any dose that results  in any of the following 
outco mes:  
• death 
• a life -threatening adverse ex perience  
Protocol : Open -Label Study  of Maraviroc in Hospi[INVESTIGATOR_480676] s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 22 of 30 
 • inpatient hospi[INVESTIGATOR_480697]  
• a persistent or sig nificant dis ability/incapacity  
Other import ant medical events may also be considered an SAE when , based on 
appropriate  medica l judgment, t hey jeopardize the s ubject or require i ntervention  to prevent 
one of  the outcomes listed.  
 
11.2.1  Serious Adverse Experience  Reporting  
Study sites w ill do cument all SA Es that occur (whether or not related to stud y drug) per 
Lifespan IRB guide lines . The collectio n period for all SAE s will beg in after informed 
consent is obtained and 28-days after last administration of Maraviroc .  
In accor dance with the  [COMPANY_007] con tractua l terms,  standard operating procedures and policies 
of the Lifespan  Institutional Rev iew Bo ard (IRB)  the Investigato r or one of the st udy 
members will report SAEs to the IRB . SAE and AE documentation  will occur in  REDC ap. 
11.[ADDRESS_617733]. Timo thy Fla nigan  shou ld be contact[CONTACT_480710].  
Phone : ([PHONE_10055]  
Pager : ([PHONE_10056] 
   
[ADDRESS_617734] ’s best  interest to contin ue.  The following is a 
list of possible reasons for study treatment disconti nuatio n:  
• Subject withdrawal of c onsent (or assent)  
• Subject is not compliant with stu dy procedures  
• Adve rse eve nt that in the opi[INVESTIGATOR_480698] b e in the best inter est of the 
subject to discontinue study treatment , includin g sto ppage criteri a for orthostatic 
hypotension  
• Protocol violation requiring discontinuation of  study t reatment  
• Drug supplier  ([COMPANY_007]) request for early termination of study , after which study drug 
cannot be reasonably pro vided to subjects at no cost to them  
• Positive pregna ncy test ( females)  
• Pursuit of comfort measures only, i npatient hospi[INVESTIGATOR_480699] f acility   
Protocol : Open -Label Study  of Maraviroc in Hospi[INVESTIGATOR_480676] s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/[ADDRESS_617735] udy treatment will undergo  an 
early discontinuation visit as soon as poss ible and will be encouraged to complete al l 
remaining scheduled  research  labwork  (excep t in the inst ance of comfort mea sures a nd 
hospi[INVESTIGATOR_6125]) . Subjects are free to withdraw from participation at any time, for any reason, 
specified or unspecified, and without p rejudice. 
Reasona ble attempts will be made by [CONTACT_29170] a re ason for subject 
withdrawals.  The reason  for th e subject’s w ithdrawal from the study will be sp ecified in 
the subject’s source documents . 
12.[ADDRESS_617736]’s best  interest to continue.    
All subjects are free t o withdraw from participation at any time, for any reason, specifi ed or  
unsp ecified, and without prejudice.  
Reasonable att empts will be made b y the investigator to provide a reason fo r subje ct 
withdrawals.   The reason for the subjec t’s w ithdrawal from the study will be specified in 
the subject’s source documents.   As not ed ab ove, subjects who discontinue study treatment 
early  should have an earl y discontinuation visit. Refer to Section  [ADDRESS_617737] subjects with 
incomplete data  (said subjects will continue to receive Maraviroc) stemming from research 
bloodwork processing errors due to mishandling o f shipments  resulting in  compromised 
fidelity  of samples. 
[ADDRESS_617738] safet y, and primary 
endpoint criteria.  Protocol violations for this study include, but are  not limite d to, the 
following:  
• Failure to meet in clusion/exclu sion crit eria 
• Use of a prohibited concomitant medica tion 
• Non-comp liance with study drug regimen, in cludi ng dose-reduction protocol  
Protocol : Open -Label Study  of Maraviroc in Hospi[INVESTIGATOR_480676] s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 24 of 30 
 • Failure to comply with Good Clinica l Practice (GCP) guidelines  will also result in a 
protocol vi olatio n. The Investigator  will det ermine if  a protocol violation will result 
in withdr awal of a s ubject. 
When a protocol violation oc curs, it will b e discus sed with the Investigator and a Protocol 
Violation Form detailing the violati on will be genera ted. This f orm wi ll be signed by [CONTACT_480711] .  Document ation of Protocol Violations  will be 
stored on IRB.net.  
14 DATA SA FETY MONITORING   
Despi[INVESTIGATOR_480700] -tolerated without significant  side effects in previous trial s 
and its current use i n patients with HIV, vigilance  and at minimum  daily a udits of subj ects’ 
objective and subjective respon se to treatment  is required given  the aggressiveness of 
SARS -CoV -2. The trial team will be responsi ble for eliciting adverse events and reviewi ng 
inpatie nt documentation daily. The trial  team has  specifically pre -define d possible  adverse 
events. Howe ver, gi ven the multitude of possible  adve rse events, the study prot ocol is not 
able to d efine all of them  in advance as many may not  lend themselves t o satisfa ctory 
definition during trial design.  Adverse events will be monit ored by [CONTACT_480712] r during the study.  
14.1 POSTURAL DIZZINESS AND ORTHOSTATIC HYPO TENSION  
In healthy volunteers, orthostatic hypotension  four ho urs a fter adm inistration of Mara viroc  
was observe d in subjects rece iving  high doses (600mg or more)  of Marav iroc versu s 
placeb o. Per package labeling, i t is recommended that users who also take an anti -
hyper tensive medication b e asked about symptoms o f orthosta tic hypo tension. Of note, in 
two Phase 3 tri als, 8% of patient s in active  (exposure ad justed rate of 14.1 per 100  pt-yrs) 
and placebo drug groups described postural dizziness, but the rate of discontinu ation due to 
syncope  or orthostatic hypoten sion betwee n the M araviroc grou p and t he placebo were 
reported at 0.5% .  Of the 840 subjects who received one dose  of Maravi roc, 2 d iscontinued 
therapy (1 due to syncope, 1 due to orthostatic hypotens ion, with an exposure adjusted ra te 
of .07 per 100 p t-yrs). 18  It is possible that the  rate o f dizziness is re lated to the length of 
therapy. In a pi[INVESTIGATOR_480701] M araviroc (300 mg BID) in 11 
colorectal cancer patients with meta stasis to the  liver, Grade 1 dizz iness was observed in 1 
patient . No patient had dizzin ess Gra de 2 or higher (e xposure adjusted rate of 5.1 per 100 
pt-yrs).[ADDRESS_617739] to see less than 
one patient exp erience orthostatic hypotension requiring discontinua tion of therapy . We 
recognize that patients with SARS -CoV -2 may be pre-dispo sed to postural dizziness and 
orthostatic hypotension  because of  their illness and poo r oral  intake , and therefore ; 
 
13 Halama N, Zoernig I, Bertel A, et a. T humoral im mune cell exploitation in colorectal cancer metastases can 
be targeted ef fectively by [CONTACT_14181] -CCR5 therapy in cancer patients. Cancer Cell. 2016;29(4):587 -601 
Protocol : Open -Label Study  of Maraviroc in Hospi[INVESTIGATOR_480676] s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 25 of 30 
 observed orthostasis  is unlikely to be from Maraviroc given the low a forementione d 
incidence in  Phas e 3 trials.   Furthermore, a stu dy of ort hostatic vital signs check ed three 
times  in one day in  elderly  patients admitted to t he hospi[INVESTIGATOR_307] (most comm only for stroke, 
infectious diseases,  or other reasons) revealed that 2/[ADDRESS_617740] trial  stoppage in the instance that an unacceptable rate o f discontinuation  due to 
orthostatic hypotension reasonably attribu table to Maraviroc is observed.  
  
14.1.1 Dose reducti on pr otocol:   
All dose-reductions will be recorded in each subj ects CFR.  
 
Patient s will be initiated on Maraviroc [ADDRESS_617741] dose  unless otherwise contra -indicated . If sympto matic  
and orthostatic,  the next dose of Maraviroc can be held  and inpatient team will be advi sed 
to review anti-hypertensive strategy, diuretic use  and consider  supplemental intravenous 
fluid if patient is anorexi c and dehydrated . Subjects  will be  re-trialed on 300 mg o f 
Maraviroc the next day. If still orthostatic, the patie nt will be re-trialed at 150 mg of 
Maraviroc the next day . Persistent orthos tasis probably or definitely at tributable  
(ortho stasis tha t develo ps aft er starting Maravi roc that was no t present at  baseline)  may 
prompt disc ontinuation of trial medicine with consideratio n of severit y of orthostasis and 
after discussion with subject and  inpatient  care team.  Withdrawing subject s will be asked t o 
participate in a  withdrawal visit as outlined  above in se ction 10.[ADDRESS_617742]  will be initiated a t Maravi roc 600 mg 
twice daily. If orthostatic  as described  above , dose -reduction to Marav iroc 300 mg  twice 
daily, followed by [CONTACT_480713] 1 50 mg twice daily will be pu rsued. Lastly, g iven the  clinica l 
context,  intubated and sedated subjects  in an intensive  care uni t will be con tinued on 
Maraviroc 300 mg  twice witho ut monitori ng for postural  dizziness of orthosta sis. 
Alternati ve causes for hypotensi on in this population should be explore d prior to dose 
reducing  Maraviroc.  
 
14 Weiss A., Grossman E., Beloosesky Y., et al.(2002) Orthostatic hypotension in acute geriatric ward : is it a 
consistent fi nding? Arch Intern Med 162:2369 –2374.  
Protocol : Open -Label Study  of Maraviroc in Hospi[INVESTIGATOR_480676] s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/[ADDRESS_617743] one dose of Maraviroc  over 34 weeks , including 426 who rece ived 
twice dai ly dosing, 1.3% o f subjects had cardiov ascula r event s. More subjects  in the 
Maraviroc grou p experi enced cardiov ascular events  than in the  placebo gro up, but th e link 
to the drug was unclear and symptoms occurred only in th ose with kno wn cardiac disease.20 
Given that our population may higher baselin e risk of cardiac events , subjects with Acut e 
Coronary  Syndrome  (ACS) within [ADDRESS_617744]-marketin g surveillanc e, one case of life -
threatening hepato toxicity, which eventually led to liver transplantation, aft er 4 doses of 
Maravir oc has been descr ibed in a  patien t who also r eceived isoniazid and trimethoprim -
sulfametho xazole. In two Phase 3 trials  of HIV patients o n Maraviroc  for an average of 34 
weeks , no overall increase in  ACTG -defined  Grade  3 of 4  (>[ADDRESS_617745] ) liver function test  
abnormalities we re observ ed in a  clinical tr ial of M araviroc in treatment -experienced 
subjects wit h HIV. [ADDRESS_617746] demons trated 
hepatocellular tran saminitis (AST and ALT >[ADDRESS_617747]) in 20 -40% of patients at t ime of 
enrollment 13 d ays (median) from  symptom onset.   In clinical  practice , hepatocellular 
transaminitis as hi gh as [ADDRESS_617748]  is freq uently e ncoun tered in hosp italized pat ients. 4 
 
15 Selzentry (Maraviroc) [package insert] N ew York, NY : [COMPANY_007]  Inc; [ADDRESS_617749], i n patients infected with HIV -1, Nat Med , 2005 , vol. 11  (pg. 1170 -2) 
Protocol : Open -Label Study  of Maraviroc in Hospi[INVESTIGATOR_480676] s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/[ADDRESS_617750] to implem ent Comm on Te rminology Cri teria for Ad verse 
Events (CTCAE) v5.0,  which incorporates change in liver function testing from b aseline to 
characteriz e AE grade. The r ecommenda tion f rom the FDA l abeling  is to obtain liver 
function tests pri or to starting the dr ug and a gain should sympto ms such as r ash occur. We 
will obtain both baseline and repeat liver function test should allergi c symptoms such as  
rash occ ur. Liver function  testing obtained per routine care will be collected daily.  
Exposure adjus ted rat es of Grade [ADDRESS_617751] infections.  Trial  data was  
obtained from patients  with H IV infection at greater r isk for infection, Immune 
Recons titution Syndrome (IRIS), and malignancy  which ma y have been secon dary reasons 
for fever . Acknowledging  the anticipated frequency of fever  and cough in SARS -CoV -[ADDRESS_617752] stoppage if there is  noted to 
be a serious adver se eve nt temporally  or other wise clearly  related to administration of the 
drug in a ny participant , and/or if there is noted to be a pattern of  deviation from natural 
history of SARS -CoV -[ADDRESS_617753] ion towards worsening symptomatolo gy and /or incre ased 
incidenc e of adverse events. The monitor may request trial stoppage if any unexpected 
grade  [ADDRESS_617754] ical Analysis Plan (SAP)  will 
be written de scribing all analys es tha t will be performed.  The SAP will contain a ny 
modification s to the analysis plan described below.   
Protocol : Open -Label Study  of Maraviroc in Hospi[INVESTIGATOR_480676] s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/[ADDRESS_617755] eristics  
The following demographic variables  at screening w ill be summarized : race, gende r, age, 
height and weight , BMI, hemodia lysis, cardiovascular dis eases (hypert ension, known 
valvular disease,  cardiomyopathi es and/or LV systolic  or diastolic dysfunction), and 
pulmon ary disease (including OSA, COPD, asthma , interstitial lung disease, cysti c fibrosis, 
bronchiectasis, lung transp lant, lung cancer, pulmon ary hypertens ion), oxygen device and 
requirement at time of enrollmen t, oxygen s aturation on ambient air at time of enrollment , 
and time from onset of sympto ms to  presentation to enrollment . 
15.3 Analysis of Endpoints  
Contin uous data  obtaine d wil l be expresse d by [CONTACT_8477] ± sta ndard deviation (SD) or 
interquartile  range, as applicable.   Categor ical variables wil l be reported as frequency and 
percentages. ICU L OS (and mechanical ventilation LOS, r especti vely) will be regressed on 
available  laborat ory a nd biomarker data using mult ivariable linear regression.  All ana lysis 
will be conducte d in a professional statist ical program . Mortality and  percent of study 
population reaching clinical improvement at Day 7 will be compared to published results  
from Remdesivir for 5 or 10 Days in P atients with Severe C OVID -19, and other available 
clinical trials including The Randomized  Evaluation of COVID -19 therapy ( RECOVERY) 
Trial.  
15.[ADDRESS_617756] ’s visi t into th e 
protocol -specific  electro nic Case Report Form (eCRF) when the information c orresponding 
to that visit is availabl e. Clinical data will be recorded using a modified  WHO –
Internati onal Severe Acute  Respi[INVESTIGATOR_480702] ( ISARIC ) 
Rapid Version C ase Record Form. Daily d iary cards recording data on a seven-category 
ordinal scale will be capture d in R EDCap.  Subjects will not b e identified by [CONTACT_480714], but will be i dentified by a subject number and initials.  
 If a corre ction is required for  an eCRF, the tim e-and-date stamps trac k the person  entering 
or updating eCRF data and creat es an  electron ic audit tr ail.  
Protocol : Open -Label Study  of Maraviroc in Hospi[INVESTIGATOR_480676] s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/[ADDRESS_617757].  
17 ADMINISTRATIVE, ETHICAL, REGULATORY CONSIDERATIO NS 
The study will be conducted ac cording t o the Declaration of Hel sinki, Protection  of Human 
Volunteers ( 21 CFR 50), Institutional  Review Boa rds (21 CFR 56), and Obligation s of 
Clinical Investigators  (21 CFR 312).  
To maintai n confide ntiality, all laborator y specimens, evalu ation forms, re ports and  other 
records wil l be i dentified by a co ded number and initial s only. The Investigator must also 
compl y with all  applicable privac y regulations (e.g., Health Insurance Portability and 
Accountability Act o f [ADDRESS_617758] ion Directive 95/46 /EC). 
17.[ADDRESS_617759] operati ng procedures and  policies of th e IRB , and  the 
Investigator will keep the IRB  inform ed as to the p rogress of the study.    
Any docu ments tha t the IRB  may need to fulfi ll its responsibi lities (such as protoc ol, 
protocol amendments, I nvestigator’s Brochure, con sent forms, in formation conce rning 
patient recruitment, pay ment or  compensation procedures, or other  pertinent informat ion) 
will be submi tted t o the IRB .  The I RB written u nconditional approval of the study protocol 
and the infor med consent form w ill be in the possession of the Invest igator bef ore the stu dy 
is initiated.  The IRB  unconditional approval s tatement will be tr ansmitted  by [CONTACT_480715] t he study .  This approva l must refer t o the study 
by [CONTACT_480716] r and s hould identif y the documents reviewed and the 
date of review.  
Protocol and/o r informed consent mod ifications or cha nges m ay not be initia ted without 
prior written IRB  approval e xcept whe n necessary to  eliminate immediate hazard s to the 
Protocol : Open -Label Study  of Maraviroc in Hospi[INVESTIGATOR_480676] s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 30 of 30 
 patients or when  the change(s) in volves only logistical or administr ative aspects of the 
study.  Such modification s will be  submitt ed to the IRB and written verification that the 
modification was s ubmit ted and subseq uently approved should be o btained.   
The IRB must be inform ed of revisio ns to other documents originally su bmitted for revie w; 
serious and/or une xpected adverse e xperiences occurri ng during the study in accordance 
with the standard oper ating procedure s and policies of the IRB; new information  that may 
affect adver sely the safe ty of the patients of the conduct o f the study; an a nnual updat e 
and/or r equest for re -approval; and when th e study has been completed.  Updated 
documents will be stored on IRB.net.  
17.3 Informed Consent Form  
Infor med consent wil l be obtained in accordance  with the Declaration of Helsinki, ICH 
GCP, US Code of Fe deral Regulations for Protec tion of Hu man Subjects ( 21 C FR 
50.25[a ,b], CFR 50.27, a nd CFR Part 56, Subpar t A), the Health Insurance Portability and 
Accountab ility Act (HIPA A, if applicable) , and loca l regulations.  
The conse nt form genera ted by [CONTACT_480717] t be approved by [CONTACT_1201] .  The  written 
conse nt document will e mbody the elements  of informed consent as  described in the 
International Conference on Harmonisation and w ill also c omply with loc al regulations.  
A properly  executed, written, informed  consent will be obtained from each subj ect prior to 
entering the subjec t into the trial.  Informat ion should be g iven in bo th oral and written 
form and subjects must  be given am ple opportuni ty to inqu ire about details of the st udy.  A 
copy of the signed  consent form will be scanned into Epic an d the original  will be given to 
the subject . 
17.[ADDRESS_617760] of 1996.   
 